Expression of the B-Cell Receptor Component CD79a on Immature Myeloid Cells Contributes to Their Tumor Promoting Effects

Dror Luger1,*, Yu-an Yang1, Asaf Raviv1, Douglas Weinberg1, Subhadra Banerjee1, Min-Jung Lee2, Jane Trepel2, Li Yang1, Lalage M. Wakefield1*

1 Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America, 2 Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America

Abstract

The role of myeloid derived suppressor cells (MDSCs) in promoting tumorigenesis is well-established, and significant effort is being made to further characterize surface markers on MDSCs both for better diagnosis and as potential targets for therapy. Here we show that the B cell receptor adaptor molecule CD79a is unexpectedly expressed on immature bone marrow myeloid cells, and is upregulated on MDSCs generated in multiple different mouse models of metastatic but not non-metastatic cancer. CD79a on MDSCs is upregulated and activated in response to soluble factors secreted by tumor cells. Activation of CD79a on mouse MDSCs, by crosslinking with a specific antibody, maintained their immature phenotype (CD11b+Gr1+), enhanced their migration, increased their suppressive effect on T cell proliferation, and increased secretion of pro-tumorigenic cytokines such as IL-6 and CCL22. Furthermore, crosslinking CD79a on myeloid cells activated signaling through Syk, BLNK, ERK and STAT3 phosphorylation. In vivo, CD79a+ myeloid cells showed enhanced ability to promote primary tumor growth and metastasis. Finally we demonstrate that CD79a is upregulated on circulating myeloid cells from lung cancer patients, and that CD79a+ myeloid cells infiltrate human breast tumors. We propose that CD79a plays a functional role in the tumor promoting effects of myeloid cells, and may represent a novel target for cancer therapy.

Introduction

The existence of cancer-induced myeloid-derived suppressor cells (MDSCs) is well-established. Tumorigenesis is almost invariably associated with the expansion of an immature myeloid cell population that shows varying degrees of differentiation blockade and can be activated to an immune suppressive phenotype [1]. Patients with cancer can show up to a ten-fold increase in circulating MDSCs, and MDSCs accumulate in tumors, lymph nodes, and spleen, constituting as much as 40% of cells in the spleen in certain mouse models [1]. However the importance of these cells in supporting tumor growth and metastasis formation has only recently been appreciated [1–3]. Metastatic cancer. CD79a on MDSCs is upregulated and activated in response to soluble factors secreted by tumor cells. In vivo, CD79a+ myeloid cells showed enhanced ability to promote primary tumor growth and metastasis. Finally we demonstrate that CD79a is upregulated on circulating myeloid cells from lung cancer patients, and that CD79a+ myeloid cells infiltrate human breast tumors. We propose that CD79a plays a functional role in the tumor promoting effects of myeloid cells, and may represent a novel target for cancer therapy.

The common characteristics of MDSCs in almost all tumor types are their myeloid origin and immature phenotype. However MDSCs are phenotypically diverse, with many different subpopulations expressing different combinations of cell surface markers depending on the cancer type and stage [12,13]. In mice the hallmark of MDSCs is the co-expression of CD11b+ and Gr1+, reflecting their immature status and close relationship to the immature myeloid cells that exist in the normal bone marrow (BM). However among cells with this common characteristic, several subpopulations have been identified that show different levels of Gr1expression (high/intermediate), as well as different proportions of the Gr1 components Ly6G and Ly6C. Granulocytic MDSCs are Ly6GLy6C while monocytic MDSCs are Ly6GLy6C and, although both subsets are immunosuppressive, they deploy different mechanisms [1]. In human cancer patients, characterization of MDSCs is more complicated since there is no human analog of the Gr1 (Ly6C/G) marker. Characterization of MDSCs in humans has included a larger number of cell surface markers (CD11b, CD33, CD14, CD15, CD34, CD13 and others), with one widely used marker combination being Lin−CD11b+CD14+HLA-
Figure 1. Increased myeloid cells and reduced B-cells associated with increasing metastatic efficiency in breast cancer models.
Metastatic 4T1 and poorly- or non-metastatic 4T07 and 67NR cell lines were implanted orthotopically in Balb/c mice, and the extent of lung metastasis and the relative representation of immature myeloid (CD11b^+Gr1^+) and mature B (CD19^+IgM^+) cells in lungs and spleen were analyzed 28 days post-inoculation. (A) Number of histologically-detectable metastases in lungs from mice inoculated with the different cell lines. N = 8 mice/
CD79a on Myeloid Cells Promotes Tumorigenesis

DR+/CD11b+/CD33+ [14,15]. From the standpoint of therapeutic targeting, it will be important to identify biomarkers of the MDSCs that are differentially expressed between normal immature myeloid cells and MDSCs, as well as to determine whether any of the markers actually play a functional role in the tumor-promoting activities of the MDSCs.

CD79a (also known as Ig-α or mb-1) is an integral membrane protein that is highly conserved among many species [16]. It is expressed at the very early stages of B cell development [17], and expression of CD79a is maintained until the last stage of maturation before differentiation to plasma cells [18,19]. In normal conditions, CD79a forms a disulfide-linked heterodimer with CD79b, and non-covalently assembles together with membrane bound IgM to form the B cell receptor signaling complex (BCR) [20,21]. The role of the dimer CD79a/b is to transmit the signal generated by antigen binding to the BCR into the cell for induction of B cell activation. Following engagement of the BCR, CD79a and CD79b are phosphorylated on their intracellular immunoreceptor tyrosine-based activation motif (ITAM) domains by Src family kinases, leading to recruitment and activation of the kinase Syk. Syk activation then triggers a signal transduction cascade leading to cytoskeletal reorganization and changes in gene expression that affects B-cell fate. The ITAM motifs of both CD79a and CD79b were found to be essential for B cell maturation [22]. Additionally CD79a/b may induce the early stages of B-cell maturation and maintain B cell survival in the periphery by tonic antigen-independent signaling [21,23].

The expression of CD79a was originally thought to be highly specific for the B-cell lineage, and in disease its presence in combination with blast antigens was considered diagnostic for B-cell acute lymphoblastic leukemia [24,25]. However, CD79a has also been found in some cases of myeloid leukemia, termed biphenotypic leukemia, in which CD79a was coexpressed with myeloid markers on bone marrow blast cells [26,27]. Currently it is not clear whether the expression of CD79a in these biphenotypic leukemias is just a marker of aberrant lineage commitment and differentiation in tumor cells, or whether it plays a functional role independent of the BCR. In the present study, while analyzing the role of B-cells in metastatic cancer progression, we made the unexpected finding that CD79a is expressed on naive immature BM myeloid cells, and on MDSCs in tumor-bearing animals. We provide evidence that CD79a plays an important functional role in maintaining the immature, immune suppressive phenotype of MDSCs and in inducing the secretion of proinflammatory cytokines. Tumor-induced CD79a expression on MDSCs was also observed in human cancer patients, suggesting that CD79a on MDSCs may be a novel target for cancer therapy.

Results

Increasing metastatic efficiency is associated with increased myeloid cells and reduced B-cells in breast cancer models

To screen the major immune responses in metastatic vs non metastatic breast cancer models we inoculated Balb/c mice orthotopically with a well-established panel of murine breast cancer cell lines with different metastatic abilities; the metastatic 4T1, the invasive but poorly metastatic 4T07 and the non-metastatic 67NR [28]. We confirmed that only the 4T1 cells generated significant numbers of metastatic colonies in the lungs (Figure 1A, B). 4T1 tumors have previously been shown to drive the generation of large numbers of MDSCs [29]. Here we showed that the increasing metastatic ability of the cell lines correlated with progressively increased levels of CD11b+Gr1+ MDSCs, both in the spleen, and in the lungs which are the principal target organ for metastasis when this model is implanted orthotopically (Figure 1C, D). The increase in MDSCs was accompanied by a significant reduction of cells in the B cell compartment (Figure 1C, E).

The B cell receptor subunit CD79a is expressed on the MDSC population that is expanded by metastatic tumors

Since not much is known about the involvement of B cells in the development of solid tumors, we analyzed the B cells further using multiple markers, including the B cell receptor-associated molecules CD79b and CD79a. To express the expression of these components we used several different antibodies. The clone HM79-12 (termed CD79-12) is specific to the extracellular domain of CD79b. There is no good monoclonal antibody specific for the extracellular domain of mouse CD79a, so we used the monoclonal antibody clone HM79-11 (termed CD79-11), described as specific for the complex CD79a/b [30]. While there was a decrease in CD19+ splenocytes in 4T1 tumor-bearing mice compared with naive mice or mice bearing non-metastatic 67NR tumors, we observed an unexpected increase in splenocytes that were positive for CD79-11 in 4T1 tumor-bearing mice (Figure 2A). We therefore investigated further to determine what cell type was staining for CD79-11 in the tumor-bearing mice. Ly6C was used as a single marker for bone marrow myeloid cells and MDSCs since we showed that CD11b, Gr1 and Ly6+ were all coexpressed at high levels in these cells (Supplemental Figure S1). We found that the majority of Ly6C+ MDSCs generated by the metastatic 4T1 model were positive for CD79-11 staining (Figure 2B). In contrast, a much smaller fraction of Ly6C+ cells showed CD79-11 positivity in naive mice, or mice bearing the non-metastatic 67NR tumors (Figure 2B). Since the CD79b-specific CD79-12 antibody did not detect this subpopulation of myeloid cells (Figure 2B), we concluded that the bi-specific CD79-11 antibody was recognizing CD79a on the myeloid cells. We then examined other metastatic models in different mouse strains. In the transplantable metastatic Lewis Lung carcinoma (LLC) model which is syngeneic to C57Bl/6, peripheral myeloid cells expanded by the tumor expressed CD79a (detected by CD79-11) (Figure 2C). We observed similar myeloid cells expressing CD79a in the genetically engineered MMTV-PyMT metastatic mammary cancer model on the FBV/N mouse strain (Figure 2D). In contrast, in the genetically engineered non-metastatic BrCa1 mammary cancer model (on a mixed mouse strain), the expanded myeloid cells did not upregulate CD79a (CD79-11) (Figure 2E).

CD79a is expressed on immature myeloid cells in naïve mice

While evaluating CD79a expression in tumor-bearing mice, we also observed a small myeloid cell population that expresses CD79a in the spleen and lungs of naive mice. Thus we hypothesized that CD79a is a member of the constellation of
Figure 2. Expression of the B-cell receptor subunit CD79a on MDSCs induced by metastatic tumors. CD79a/b expression on the Ly6C+ myeloid cell population in multiple tumor models was assessed by flow cytometry. (A) Expression of the B-cell markers CD19 and CD79a/b on splenocytes from naive and 67NR and 4T1 tumor-bearing mice. (B) Ly6C+ and CD79a/b expression on viable leukocytes from lungs and spleens of Balb/c mice bearing 67NR or 4T1 tumors at day 28 post-inoculation. The box indicates the immature myeloid population. CD79 on myeloid cells is recognized by the CD79-11 but not the CD79-12 antibody. (C) CD79a expression on MDSCs was also evaluated in the Lewis Lung Carcinoma transplantable metastatic lung cancer model (C57Bl/6 background). (D,E) Similar evaluation was done in two genetically-engineered models of breast cancer; the metastatic MMTV-PyMT model (D) on the FVB/N background (age 3 months) and the non-metastatic Brca1 model (E) on a mixed genetic background (age 6 months).

doi:10.1371/journal.pone.0076115.g002

Factors secreted by metastatic tumor cells expand CD79a-expressing BM myeloid cells and enhance their migration

Based on the significant effect of primary tumors from metastatic models on the expansion of CD79a+ immature myeloid cells, we hypothesized that soluble factors secreted by these tumors might mediate this effect (differential cytokine secretion by the metastatic 4T1 and the non-metastatic 67NR cell lines is described in supplementary table s1). To test this hypothesis we used a Transwell® co-culture system with the different tumor cell lines placed in the wells and naive BM myeloid cells in the insert, with a small pore-size membrane such that only soluble factors could be transferred between the two compartments. After 48 h of incubation we found that the metastatic 4T1 cell line increased the expression of CD79a on BM myeloid cells whereas the non-metastatic 4T07 or 67NR cell lines had little effect (Figure 4A). Secreted factors from the metastatic 4T1 cells also induced the selective expansion of CD79a expressing myeloid cells (Figure 4B), and enhanced their migration (Figure 4C). The CD79a+ myeloid cells were intrinsically more migratory than the CD79- cells in response to factors secreted by the 4T1 cells. Based on these results we concluded that soluble factors secreted by the metastatic cells induce the expression of CD79a on immature myeloid cells of BM origin and modify their phenotype. To try to identify these factors, conditioned medium from the metastatic 4T1 and the non-metastatic 67NR cell lines was analyzed for differential expression of candidate cytokines using Aushon Protein Arrays. Several cytokines were found to be significantly more highly expressed by 4T1 compared to 67NR cells (Supplemental Table S1). These included GM-CSF, IL-6, and IL-1β. However, none of these individual cytokines showed any effect on CD79a expression in the naive BM cells (data not shown), and TGF-β, G-CSF and M-CSF were also tested and shown to be ineffective. Thus either some other as yet unidentified factor is involved, or the upregulation of CD79a requires the combined activity of multiple factors.

Stimulation of naive BM myeloid cells through CD79a enhanced their migration, their granulocytic phenotype and their suppressive effect on T cell proliferation

To determine whether CD79a has a functional role in MDSC migration we used the polyclonal CD79a(v-20) antibody to crosslink and thus activate CD79a. In vitro crosslinking of CD79a enhanced significantly the migration of BM myeloid cells (Figure 5A). Further analysis of the functional role of CD79a in BM myeloid cells showed that crosslinking with anti CD79a maintained the immature granulocytic phenotype (CD11b+Gr1+) while preventing differentiation toward a macrophage phenotype when the myeloid cells were co-cultured with GM-CSF (Figure 5B). One of the main characteristics of MDSCs is their ability to suppress anti-tumor T cell activity [1], so we next tested whether crosslinking CD79a has an effect on inhibition of T cell proliferation by BM myeloid cells. To that end, sorted splenic T cells were labeled with CFSE and were stimulated with anti-CD3/CD28 in the presence of different ratios of naive myeloid cells from SCID mice with the addition of anti CD79a(v-20) or isotype control. As others have demonstrated, we found that BM-derived myeloid cells have a natural ability to suppress T cell proliferation, and this effect is dose-dependent (Figure 5C). However, the suppressive effect of myeloid cells on T cell proliferation was further increased when the myeloid cells were stimulated with anti CD79a(v-20) (Figure 5D). In addition we showed that conditioned medium from LLC tumor cells alone had a suppressive effect on T cell proliferation, but the combination of myeloid cells and tumor...
conditioned medium resulted in a greater suppressive effect (Figure 5C), again suggesting the possibility that a tumor-secreted factor can activate MDSCs through CD79a.

Stimulation of myeloid cells through CD79a induces the secretion of tumor-promoting cytokines and activation of downstream signaling pathways

To further address the effect of stimulation of CD79a on the phenotype of the immature myeloid cells, we performed cytokine protein arrays using supernatants from co-culture of BM myeloid cells with anti CD79a(v-20), isotype control or 4T1 condition media (CM). We also performed a control array for the 4T1 CM alone. Stimulation of BM myeloid cells by crosslinking CD79a induced the secretion of several cytokines associated with tumor and metastasis promotion, in particular IL-6, RANTES, TNFR-II, CXCL16 and CCL22 (Figure 6A,B). A similar pattern was seen on stimulation of the BM myeloid cells with 4T1-conditioned medium, suggesting as above that conditioned medium from metastatic cells contains a factor that can activate CD79a. The increased secretion of IL-6 and CCL22 was confirmed by ELISA (Figure 6C,D). Both IL-6 and CCL22 were previously implicated in promoting tumorigenesis, by inducing expansion of immature myeloid cells and recruitment of Treg respectively [34,35].

B-cell receptor signaling through the CD79a/b heterodimer involves phosphorylation of the ITAM domains of CD79a/b leading to recruitment and activation of the kinase Syk, formation of a signaling complex around the protein BLNK, and activation of downstream pathways [21]. To explore possible signaling mechanisms induced by activation of CD79a, BM myeloid cells were stimulated with anti CD79a(v-20) and protein was extracted at different time points. Crosslinking CD79a in BM myeloid cells induced an early phosphorylation of Syk and BLNK (Figure 6E), suggesting that some of the same downstream pathways may be activated by CD79a in myeloid cells and in B-cells. Later phosphorylation of ERK and STAT3 was also observed (Figure 6E), with STAT3 activation possibly reflecting autocrine stimulation by the increased IL-6 secretion that occurs on CD79a activation (Figure 6D).

CD79a expressing myeloid cells promote tumor growth both at the primary and the metastatic site

MDSCs have previously been shown to infiltrate primary tumors and metastases [1]. By immunofluorescence, we showed that the infiltrating MDSCs in metastases from the LLC model co-express the myeloid marker Gr1 together with CD79a, as detected with either anti CD79a-11 or anti CD79a(v-20) antibodies (Figure 7A). Quantifying the images, we confirmed that the lung metastases had significantly higher levels of total MDSC infiltration when compared with non-involved areas of the metastasis-bearing lungs, or with naive lungs, and we showed that the majority of the MDSCs in the metastases and the uninvolved lung from tumor-bearing mice were CD79a+ (Figure 7B). The contribution of CD79a to the tumor-promoting effect of myeloid cells was assessed in two ways. To elucidate the role of CD79a-expressing myeloid cells on primary tumor formation, two myeloid cell populations (Ly6C<sup>+</sup>CD79a<sup>-</sup> and Ly6C<sup>+</sup>CD79a<sup>+</sup>) were sorted from BM cells of 4T1-tumor bearing SCID (Balk/c) mice harvested 20 days after tumor cell inoculation. Cells from either population were co-inoculated together with 4T1 tumor cells into the mammary fat pad of immune competent mice, and tumor weight was evaluated at 14 days post inoculation. The CD79a<sup>+</sup> myeloid cells caused a significantly greater stimulation of tumor growth (Figure 7C). To examine the role of CD79a<sup>+</sup> myeloid cells in lung metastasis, Ly6C<sup>+</sup> myeloid cells were sorted from bone marrow of naive C57Bl/6 mice and incubated ex vivo with anti CD79a(v-20) or isotype control antibody for 24 h. Thereafter myeloid cells were co-injected together with luciferase-expressing LLC cells into the tail vein of syngeneic mice. Lung metastasis burden was assessed by luciferase imaging after 21 days, and the myeloid cells stimulated with anti-CD79a(v-20) significantly enhanced metastasis compared with unstimulated myeloid cells (Figure 7D). Together, these data suggest that activation of CD79a on myeloid cells contributes to the promotion of tumorigenesis at the primary and metastatic sites.

CD79a is expressed on myeloid BM cells from normal human donors and is upregulated on myeloid cells circulating in blood from cancer patients

The data thus far support the hypothesis that in mouse models of metastatic disease, the tumor can increase expression of CD79a on immature myeloid cells, thereby maintaining a more immature phenotype with immunosuppressive and tumor promoting characteristics. We next wanted to know whether CD79a is expressed on myeloid cells in humans. We found that CD79a is expressed on immature BM-derived myeloid cells from normal human donors (Figure 8A), as was seen in mice. Importantly we found that CD79a was significantly upregulated on myeloid cells in peripheral blood from lung cancer patients in comparison to normal donors (Figure 8B,C,D). Furthermore, immunofluorescence staining of human breast tumor sections showed tumor infiltration by myeloid cells (CD11b+) that express CD79a (Figure 8E). 34% of the breast cancer samples examined (n = 60 total) were positive for CD79a<sup>+</sup> infiltrating myeloid cells. Information was not available on whether these patients had distant or only local disease. Thus CD79a expression on immature myeloid cells and MDSCs is seen in both humans and mice. However, it will be important to determine in humans whether elevated CD79a expression on myeloid cells correlates with the metastatic state, as it appears to in mouse, and whether it might be useful as a prognostic marker.

Discussion

The best-characterized role of CD79a is as part of the B cell receptor signaling complex. CD79a expression is seen very early in B cell lineage development in bone marrow, and it has an essential role in B cell development, survival and activation [23,36]. In the present study we unexpectedly found expression of CD79a on immature BM-derived myeloid cells, and on tumor-induced MDSCs in multiple mouse tumor models and in human cancer...
CD79a on Myeloid Cells Promotes Tumorigenesis
patients. Most importantly, activation of CD79a on MDSCs enhanced tumorigenesis and metastasis in the mouse models, suggesting a functional role for myeloid CD79a in promoting tumor progression. Mechanistically, we showed that stimulation of MDSCs through CD79a maintained their immature status, enhanced their suppressive effect on T cell proliferation, stimulated their migration, and induced the secretion of pro-tumorigenic cytokines (see schematic in Figure 9).

CD79a expression on myeloid cells was first reported in some cases of acute myeloid leukemia (AML) which showed co-expression of CD79a with myeloid markers [26,27]. In these studies the proportion of myeloid cells that co-expressed CD79a ranged from 0–90% depending on the study. Exploring this heterogeneity, Bhargava and colleagues showed by immunohistochemistry that the detected level of CD79a on myeloid cells is dependent on the antibody clone used, revealing 30–45% AML cases positive for CD79a using the clones 11D10 and HM57 [37]. The highest frequency of CD79a expression was detected using antibodies specific for the intracellular domain. Interestingly, in the same study they also found CD79a expression on 30–40% of normal myeloid precursors in the early stages of maturation, while bands and mature neutrophils did not stain with these antibodies. However, the authors raised the possibility that the apparent expression of CD79a on normal immature myeloid cells might be an immunohistochemical artifact.

In the present study we showed by FACS-based immunophenotyping that CD79a was expressed on the majority of naive BM myeloid cells, as well as on a small population of peripheral myeloid cells in all the mouse models that we examined. Since there is no good monoclonal Ab for the extracellular domain of CD79a, we used a monoclonal Ab (clone HM79-11a) described as reactive with the dimer CD79a/b. By this approach, we found that immature BM myeloid cells were positive for CD79a/b (detected with HM79-11), but not for CD79b (as detected with the CD79b-specific clone HM79-12), or for other B cell markers. Similar results were obtained using a polyclonal Ab generated against the extracellular domain of CD79a (CD79a-poly), though staining with this antibody was much weaker. CD79a expression on immature BM myeloid cells from SCID mice was further confirmed by intracellular staining using clone F11-172. The expression of CD79a but not CD79b in immature myeloid cells was also confirmed at the mRNA level in BM myeloid cells from SCID mice, which lack the lymphoid compartment. By Western blots analysis, CD79a in MDSCs had a molecular weight of 37 KDa, slightly lower than the lowest band seen in B cells. CD79a is known to exist as multiple forms due to alternative splicing and glycosylation variants [38], and it will be interesting to characterize this myeloid isoform further. Overall, our flow cytometry results using multiple antibodies and our gene expression data are in accordance with the immunohistochemical analysis of Bhargava et al. [37], and confirm that CD79a is expressed early in the myeloid lineage. Similar to our results in the mouse models, we found that normal BM and a fraction (10–15%) of circulating myeloid cells from normal human donors expressed CD79a. Together, these observations suggest that CD79a may play a role in early myeloid development, and not be restricted to the B-cell lineage in normal hematopoiesis. It is intriguing that one alternate model of hematopoietic cell diversification and development proposes that commitment to the B cell and T cell lineages occurs through myeloid/B cell and myeloid/T cell bipotential stages [39,40]. This contrasts with the classical model in which T and B cells develop from a common lymphoid progenitor after initial separation of distinct myelo-erythroid and lymphoid lineages. Conceivably the expression of CD79a that we observe on immature myeloid cells may reflect an early stage in the diversification of myeloid cells and B cells from such a bipotential myeloid/B cell progenitor. However, the functional role of CD79a in normal immature myeloid cells is not clear, as to date no abnormalities in myelopoiesis have been described in the CD79a knockout mouse [41].

In normal conditions and in acute inflammation, immature myeloid cells rapidly undergo differentiation into the different mature myeloid cells (macrophages, granulocytes or dendritic cells) either in the BM, or following recruitment to the periphery. However in chronic inflammation and cancer there is aberrant expansion of certain immature myeloid populations, including MDSCs [1]. Since we found that MDSCs expanded by metastatic tumors maintain the CD79a expression seen in immature BM cells, we asked whether CD79a plays a role in myeloid differentiation. Knockout mouse studies have shown that both CD79a and CD79b are necessary for differentiation of pro-B to pre-B cells in response to antigen engagement of the BCR [41]. However, dimers of the CD79a/b or of CD79a/a cytoplasmic domains alone can induce tonic antigen-independent signaling in B cell progenitors to support early stage differentiation [42,43]. Furthermore, cross-linking of CD79a in early lineage B-cells was sufficient to induce downstream tyrosine phosphorylation though the functional consequences were not explored [44]. Here we showed that BM myeloid cells activated by CD79a cross-linking maintained their immature phenotype (CD11b+Gr1+F4/80−) on treatment with GM-CSF, whereas GM-CSF alone promoted the differentiation toward the F4/80+ macrophage phenotype. Since we did not find CD79b on immature myeloid cells, our data suggest that CD79a can function independently of CD79b to generate signals that maintain the immature state in cells of the myeloid lineage.

We also observed other important consequences of CD79a activation that could contribute to the pro-tumorigenic effect of the MDSCs. Cross-linking CD79a enhanced MDSCs migration, a finding that is in accordance with our immunofluorescence observations showing that a large proportion of MDSCs infiltrating into lung metastases express CD79a. Furthermore, cross-linking CD79a on MDSCs also increased their inhibitory effect on T cell proliferation and changed their cytokine expression profile. The cytokines that were most significantly upregulated following CD79a stimulation of MDSCs were IL-6 and CCL22. IL-6 is a major activator of STAT3 signaling and it is associated with poor prognosis in different cancers [45,46]. IL-6 was found to be involved in tumor growth and metastasis spread by inducing expansion of MDSCs and immune suppression [34,47], and it can
Figure 5. CD79a activation on myeloid cells affects migration, differentiation and T-cell suppression.

(A) The effect of stimulation with anti CD79a(v-20) on the migration of FACS-sorted Ly6C+ immature myeloid cells from naive bone marrow was tested in a Transwell® system for 48 h. Results are mean ± SEM; n = 3 determinations. (B) Bone marrow cells from naïve SCID mice were stimulated with anti- CD79a(v-20) (5 µg/ml) for 48 h. CD79a on Myeloid Cells Promotes Tumorigenesis
96 h with or without added GM-CSF in low (2%) normal mouse serum. The effect of anti CD79a(v-20) on myeloid cell differentiation status was assessed using immature myeloid (CD11b<sup>+</sup>Gr1<sup>+</sup>), granulocytic (Gr1<sup>-</sup>) and macrophage (F4/80<sup>-</sup>) markers. Data shown are representative of two independent experiments. (C) The effect of immature myeloid cells stimulated with anti CD79a on proliferation of CD4 T cells. Immunopurified naïve CD4<sup>+</sup> T cells ("T") labeled with CSFE were stimulated with anti CD3/CD28 with the addition of the indicated ratios of FACS-sorted immature BM myeloid cells ("M") with or without the addition of anti CD79a(v-20) antibody. Cell divisions were measured by flow cytometry analysis for CFSE dilution. Dose response for effect on T-cell division of myeloid cells added at the indicated ratio, with the addition of anti CD79a(v-20) or isotype-matched control antibody is shown. (D) The effect of LLC tumor cell conditioned medium (CM) (ratio 1/5 v/v), myeloid cells and the combination of both on T cells proliferation. Data shown are representative of two independent experiments.

doi:10.1371/journal.pone.0076115.g005

also affect the tumor parenchyma by inducing a more malignant, cancer stem cell phenotype in breast cancer cells [48,49]. CCL2,22 is a major recruiter of T<sub>reg</sub>, which support the immune suppression role of MDSCs [35]. Thus secretion of these two cytokines by MDSCs following stimulation through CD79a could clearly enhance the pro-tumorigenic activity of these cells.

Currently the endogenous ligand for CD79a is not known, and it is not clear how the activated CD79a signals to induce pro-tumorigenic responses in MDSCs. As an ITAM-bearing protein, CD79a joins an increasing family of myeloid adaptor molecules and receptors that use ITAMs as part of their signaling mechanism. [30, 31]. ITAM-containing signaling adaptors are generally associated with activation of cellular responses, though some ITAM adaptors in myeloid cells can have an inhibitory role [32]. Here we showed that co-culture of MDSCs with metastatic tumor cells, or exposure of MDSCs to tumor cell-conditioned medium, sustained the expression of CD79a in MDSCs in culture, and induced many of the same responses as did activation of CD79a by the anti-CD79a antibody. Thus our data strongly suggest that a factor secreted by tumor cells may be responsible for these activities. However, when we tested the candidate cytokines that were most differentially expressed between the metastatic 4T1 and non-metastatic 67NR cells (GM-CSF, G-CSF, M-CSF, IL-6, IL-1β, TNFα), we did not find any with the expected activity on MDSCs, so the identity of the secreted factor remains unknown. CD79a has a very short extracellular domain, making it unlikely that it engages ligand directly. Increasing evidence suggests that ITAM-bearing adaptor molecules can interact with many different classes of receptor for signaling, including toll-like receptors, tumor necrosis factor receptors, cytokine receptors that use the Jak-STAT signaling pathway, and integrins [33]. Interestingly, myeloid cells have a large number of C-type lectin receptors that recognize damaged and aberrant cells, and some of these receptors are dependent on ITAM adaptor proteins for signaling [34]. Finding the ligand/receptor pair that interacts with CD79a will be important for elucidating the role of CD79a in myeloid cells.

In B-cells, engagement of the B-cell receptor leads to phosphorylation of the CD79a/b heterodimer and consequent recruitment and activation of the tyrosine kinase Syk [21]. Syk activation organizes two signaling complexes which activate secondary messenger pathways including the Ras/ERK, NFAT and NF-kB pathways, ultimately leading to altered cytoskeletal organization and changes in gene expression [21]. Here we found that cross-linking CD79a in immature BM myeloid cells resulted in early Syk phosphorylation. Thus downstream signaling from CD79a in myeloid cells may involve some of the same players as seen in B-cells. CD79a is unique among ITAM-bearing proteins, and differs importantly from CD79b, in having an additional tyrosine (Y204) outside the ITAM motif that is critical for B-cell activation and proliferation. In B-cells, phosphorylation on this site recruits BLNK which nucleates the signaling complex that activates the Ras/ERK pathway [35]. We did observe an increase in BLNK phosphorylation on stimulation of CD79a, and it will be interesting to determine if this unique phosphorylation site on CD79a is key to the recruitment of downstream mediators in the myeloid cells. We also observed a later STAT3 phosphorylation that probably reflected the establishment of an IL-6 autocrine loop following CD79a stimulation. STAT3 activation has previously been implicated in promoting increased survival and proliferation of myeloid progenitor cells, as well as in blocking their differentiation [1].

In summary, we have demonstrated expression of the B cell receptor subunit, CD79a, on immature myeloid cells and MDSCs in multiple mouse models of cancer and different mouse strains. CD79a was found also on normal human immature BM myeloid cells and upregulated on peripheral MDSCs from cancer patients. We have provided evidence that CD79a activation by tumor-derived factors contributes importantly to maintaining the immature phenotype in myeloid cells and to enhancing their immune suppressive and pro-tumorigenic activities. A number of strategies to target MDSCs are currently being explored in the field, including induction of differentiation with agents such as all-trans retinoic acid; inhibition of expansion by targeting factors such as SCF and VEGF; and inhibiting function with agents such as COX2 inhibitors [1]. With our discovery of a functional role for CD79a in the tumor suppressive effects of MDSCs, it will be interesting to determine whether targeting CD79a or downstream signaling events would add to this arsenal of anti-MDSC approaches. Drugs such as fostamatinib, an inhibitor of the Syk kinase that has shown some clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia [56,57], could conceivably be repurposed to provide therapeutic benefit in solid tumors. While a recent Phase I trial did not show any benefit of fostamatinib monotherapy in heavily pre-treated patients with solid tumors [58], understanding the role of CD79a signaling and Syk kinase in MDSCs may prompt investigation of Syk kinase inhibitors as immunomodulatory agents in combination therapy protocols. Further study is warranted to elucidate this new signaling pathway in MDSCs and its modulation by tumor-derived factors.

Materials and Methods

Cell lines

The malignant cell lines 67NR, 4T07, and 4T1 were all established from a single spontaneously arising mouse mammary tumor in a BALB/c mouse [28], and were the generous gift of Dr. Fred Miller, Karmanos Institute, Detroit, MI. The Lewis lung carcinoma (LLC) cells stably expressing a luciferase-GFP fusion protein were obtained from Dr. Chi-Ping Day, NCI [59]. Cells were cultured in DMEM/10% fetal bovine serum.

Mice and tumorigenesis studies

All animals studies were performed under a protocol (LC-070) approved by the National Cancer Institute Animal Care and Use Committee, in accordance with Association for Assessment and Accreditation of Laboratory Animal guidelines and policies established by the NIH. Balb/c, C57Bl/6 and SCID (Balb/c) mice for tumor implantation and immunophenotyping of naive mice were purchased from Charles River, Frederick, MD and...
Figure 6. CD79a activation on myeloid cells alters cytokine expression and activates signaling pathways. The secretion of cytokines and chemokines by Ly6C+ immature BM myeloid cells isolated from SCID mice and cultured for 48 h under the indicated conditions was assessed using a membrane-based cytokine array. (A) Arrays of conditioned media from culture of BM cells treated with anti-CD79a(v-20), isotype control, or 4T1 tumor cell CM, together with a control array for 4T1 CM alone. (B) Relative levels of proteins with the most significant change (indicated by boxes)
Figure 7. CD79a expression and activation on myeloid cells contributes to their pro-tumorigenic effects in vivo. (A) Immunofluorescence of normal lung and metastasis-bearing lungs in the LLC model. Infiltrating Gr1+CD79a+ myeloid cells are clearly visible at the outer edge of a lung metastasis but are rare or absent from normal lung tissue. The dotted line marks the outer boundary of the metastasis. Scale bar: 40 μm. (B) Quantification of lung infiltrating Gr1+CD79a+ and Gr1+CD79a- myeloid cells: Analysis was done for 3 groups: normal lung, uninvolved lung tissue from metastasis bearing lung, and lung metastasis. Each data point represents the mean of 5 fields (500 μm²) for a given sample and results are given as mean +/- SEM. (C) Immature BM cells from C57Bl/6 mice were FACS sorted into two groups of Ly6C+CD79a+ and Ly6C+CD79a- myeloid cells. The sorted myeloid cells were co-inoculated together with LLC tumor cells subcutaneously in C57Bl/6 mice at a ratio of 25:1 myeloid:tumor cells. Tumor weight was measured at day 14 post-inoculation. Results are mean +/- SEM (n = 5). (D) Ly6C- BM-derived myeloid cells from naïve mice were isolated by FACS and cultured with anti CD79a(v-20) or isotype control antibodies for 24 h. Treated myeloid cells were then harvested and injected i.v. together with luciferase-expressing LLC cells (2 × 10⁶ myeloid cells and 10⁴ LLC tumor cells/mouse) in C57Bl/6 mice. Metastatic burden was quantitated from in vivo luciferase signal at day 15 after implantation. Results are median with interquartile range (n = 10 mice/group).

doi:10.1371/journal.pone.0076115.g007
Figure 8. CD79a expression on myeloid cells from normal human donors and in cancer patients. (A) Expression of CD79a on immature myeloid cells (characterized as CD11b+CD33+) in BM from a normal human donor. (B) Representative FACS profiles of immature myeloid cells in peripheral blood (live leukocyte gate) from a normal donor and a lung cancer patient. (C) Immature myeloid cells (CD11b+CD33+) expressing CD79a in normal donors and lung cancer patients as % of live leukocytes. Results are mean +/- SEM (n = 5). (D) Histogram showing proportion of CD79a+ myeloid cells relative to total myeloid cells. Results are mean +/- SEM (n = 5) (E) Representative immunofluorescence staining of infiltrating CD79a+ myeloid cells.
were used at 8–10 weeks old. Two genetically engineered mouse models of breast cancer were also used. The MMTV-PyMT model (FVB/N background) is highly metastatic to the lung [60], and was obtained from Dr. Kent Hunter, NCI. The BrCaco/co;MMTV-Cre;Trp53+/- model ("BrCa1" on mixed C57Bl/6, FVB/N background) forms large primary tumors but is rarely metastatic [61], and was obtained from Dr. Chuxia Deng (NIDDK). Tumor-bearing MMTV-PyMT mice were analyzed at 3 months of age at which time 90% of the mice had developed lung metastases, while tumor-bearing BrCa1 mice were analyzed at 6 months of age. For syngeneic transplant studies, the cell lines 4T1, 4T07, (4 × 10⁴ cells/mouse) and 67NR (6 × 10⁴ cells/mouse) were surgically implanted in the number 4 mammary fat pad of Balb/c mice. The Lewis Lung (LLC) cell line was implanted (4 × 10⁴ cells/mouse) subcutaneously on the flank of wildtype C57Bl/6 mice. Tumor growth was measured by calipers and tumor volumes were calculated as v = 0.52L*S², where L is the longest diameter and S is the orthogonal shorter diameter. Tumor-bearing mice were euthanized 3–5 weeks post-inoculation. At necropsy, lungs were inspected for the presence of gross metastases and the largest lobe was fixed in neutral buffered formalin for histopathological assessment of metastatic burden and for localization of infiltrating immune cells by immunofluorescence. The remaining lung lobes were used for immunophenotyping. Bone marrow and peripheral blood were also collected for immunophenotyping (see later), and primary tumors were fixed in formalin. To assess the role of CD79a+ myeloid cells on primary tumorigenesis, Ly6CxCD79-11+ and Ly6CxCD79-11+ myeloid cells were prepared by FACS sorting from bone marrow of 4T1 tumor-bearing SCID mice harvested 20 days after tumor cell implantation. The myeloid cells were orthotopically co-implanted with 4T1 tumor cells in immunocompetent Balb/c hosts (1 × 10⁶).
myeloid cells: $1 \times 10^5$ tumor cells), and the weight of the primary tumor was determined after 14 days. To assess the role of CD79a in metastases, $1 \times 10^6$ luciferase-labelled LLC cells were injected into the tail vein of immunocompetent C57Bl/6 mice, either alone or with $1 \times 10^6$ myeloid cells that had been FACS-sorted from bone marrows of naive C57Bl/6 mice and treated ex vivo for 24 h with either anti-CD79a(v-20) or isotype control antibody (10 μg/ml). The lung metastatic burden at the endpoint was determined by in vivo bioluminescent imaging following intraperitoneal injection of 150 mg/Kg luciferin substrate using a Xenogen IVIS system (Caliper Life Sciences, Alameda, CA), and confirmed by histopathological analysis of H&E stained sections of formalin-fixed lung.

**Human clinical specimens.** Studies with human clinical material were done under an NIH Office of Human Subjects Research exemption (OHSRP 11416) that allows for the use of de-identified specimens for biological research. Fresh blood from normal donors was obtained from the Blood Bank at the National Institutes of Health Clinical Center, Bethesda. Anonymous blood samples from consented human lung cancer patients were purchased from the Cooperative Human Tissue Network (CHTN) and shipped overnight in EDTA tubes on ice for analysis the next day. Patients tumor grade was 1–3, and all patients were receiving FACS sorting

**Table 1.** The following anti-CD79a and CD79b antibodies were used in the mouse studies for flow cytometry and/or for in vitro cell stimulation.

| Antibody | Clone | Antigen | Source | Catalog # |
|----------|-------|---------|--------|-----------|
| CD79-11 | HM79-11 | CD79a/b | AbD Serotec (Raleigh, NC) | MAC1821FB |
| CD79-12 | HM79-12 | CD79b | BioLegend (CA) | 132804 |
| CD79a | F11-172 | CD79b intracellular | BioLegend (CA) | 133106 |
| CD79a(v-20) | (polyclonal) | CD79b extracellular peptide | Santa Cruz Biotechnology (CA) | sc-8503 |

DOI:10.1371/journal.pone.0076115.t001

Cells surface Fc receptors were blocked by incubation with anti-Fc (CD32/CD16, clone 93) (BioLegend, CA) for 15 min. Mouse blood was stained with the relevant antibodies in FACS buffer for 30 min at 4°C, washed and stained with 7-AAD to enable exclusion of dead cells. For intracellular staining, cells were fixed in paraformaldehyde 2% for 15 min, washed and permeabilized with Saponin 0.01% and stained with the relevant antibodies. Anti-mouse antibodies used for FACS staining (BioLegend, CA) were the following: CD11b (M170), Gr1 (RB6-8C5), IgM (MM-30), CD19 (6D5), B220 (30-F11), Ly6C (HK1.1), Ly6G (1A0), F4/80 (BM8). For mouse studies, the antibodies, anti-CD79a and CD79b used for flow cytometry and/or for in vitro cell stimulation are described in table 1.

For FACS analysis of human samples the following antibodies (eBiosciences, CA) were used: CD11b (CBRM1/5), CD33 (HM3-4), CD79b (CB3-4), CD19 (B19.12). Anti CD79a (ZL7-4) was purchased from AbD Serotec, NC. Flow cytometry was performed on a FACS Calibur (BD Biosciences, CA) instrument and analyzed with FlowJo software (FlowJo, OR). FACS sorting was performed on a FACS Aria (BD Biosciences, CA). FACS analysis was done by gating on leukocytes using forward scatter and side scatter, followed by gating on live cells (negative for 7-AAD).

**Quantitative real-time PCR (qRT-PCR)**

For analysis of CD79a and CD79b gene expression, BM cells were isolated from SCID mice and FACS sorted for Ly6C+ myeloid cells. Splenocytes from naive Balb/c mice were used as a positive control. Total RNA was prepared using TRIzol (Invitrogen) until the step of collecting the aqueous fraction. Total RNA was then extracted from the aqueous fraction using the RNeasy kit (Qiagen Inc, Valencia CA, USA) according to the manufacturer’s instructions. cDNA synthesis was carried out using M-MLV reverse transcriptase (Invitrogen). All quantitative RT-PCR data were normalized to cyclophilin A (PPIA) as an internal control for each sample. The following primers were used: CD79a Forward, (5'-CAGTCAGGGTTCTAGCCCCCTCAT-3'); and Reverse, (5'-CCTGTTTGGTCCCGCATGCC-3'); CD79b, Forward (5'-GCTTTCTCTACGGTCAGCGCCGT-3'); Reverse (5'-GTCTG-GTACATGTTCTAGCACCCCTCA-3'); PPIA, Forward (5'-CATA-CAGGTCCTGGCACATCTGTG-3'); Reverse (5'-AGACCA-CATGCTTGCCATCCAG-3').

**Western Blot**

For western blot analysis of CD79a and CD79b, single cell suspensions of BM and spleen were prepared from wildtype (WT) Balb/c or C57Bl/6 mice and immunodeficient SCID mice, in the...
naive or tumor-bearing state. Bone marrow cells were pooled from 5 mice. Cells were lysed in Mem-PER buffer (Pierce). Total protein (40 μg) was electrophoresed on 4 to 20% Tris-glycine gels and transferred to polyvinylidene fluoride membranes. Membranes were blocked with 5% nonfat dry milk in Tris-buffered saline with 0.1% Tween-20 for 45 minutes at room temperature, and were then incubated with primary antibody solutions overnight at 4°C. The primary antibodies used were as follows: anti-CD79a (HM79-11, AbD Serotech), anti-CD79b (HM79-12, BioLegend, CA), anti-CD79a (F11-172, BioLegend, CA), anti-β-actin (Sigma). For detection of signaling components, the following antibodies (Cell Signaling Technologies, Beverly, MA) were used: anti-Syk (clone D15Q), anti-phospho-Syk (clone D7C1), anti-ERK1/2 (p42/p44, 9102), anti-phospho-ERK (clone E10), anti-STAT3 (clone 79D7) and anti-phospho-STAT3 (clone D3A7). Anti-BLNK (polyclonal, bs-2748R) and anti-phospho-BLNK (polyclonal, bs-3054R) were purchased from Bioss Inc, Woburn, MA. All secondary antibodies were HRP-conjugated goat anti-Armenian hamster (Rockland, PA), used at a 1:1,000 dilution. Secondary antibodies were applied for 2 hours at room temperature, followed by incubation with chemiluminescent reagent (Super Signal; Thermo Scientific Pierce Protein Research Products, Rockford, IL, USA) and exposure to autoradiography film (Eastman Kodak Co., Rochester, NY, USA).

Suppression of T cell proliferation

To test the effect of MDSCs on suppression of T cell proliferation we used the carboxy-fluorescein-diacetate-succinimidy-ester (CFSE) labeling assay [63]. T cells were negatively isolated by separation with magnetic beads (Pan T Cell Isolation Kit; Miltenyi Biotec). T cells were suspended in RPMI-1640 medium (1×10^6 cells/ml). CFSE (Sigma-Aldrich) was added to the cell suspension at a final concentration of 0.05 μM and incubated for 15 min at room temperature in darkness. Labeled cells were washed 3 times with PBS, re-suspended into RPMI-1640 media and counted. Ly6C^+ myeloid cells were isolated from SCID mice BM cells by FACS sorting (Aria, BD). T cells and myeloid cells were co-cultured in RPMI-1640 medium containing 1% normal mouse serum. Cells were plated in round bottom 96-well plates in triplicates at ratio of 1:1, 2:1, 3:1, 9:1 T cells/myeloid cells at a final number of 1×10^6 cells/well. In some experiments, anti CD79a antibody (HM79-11, Serotec) was added at 10 μg/ml, or conditioned medium from 4T1 cell culture was added at 1/5 final dilution. After 5 days of culture, cells were collected, triplicate wells were pooled and cells were stained with anti-CD4 and analyzed by flow cytometry for CFSE dilution.

Transwell-based assays to assess effects of tumor cell secreted factors on myeloid cell expression of CD79a, expansion and migration

To determine the effect of tumor cell secreted factors on CD79a expression and expansion of myeloid cells, 4T1 or 67NR tumor cells were plated (3×10^5 cells/well) in the bottom chamber of a 24-well Transwell® system with 0.4 μm pore size insert (BD Falcon, CA). 24 h later, 3×10^5 BM or spleen cells were placed in the insert and co-incubated with the tumor cells for 48 h in complete media containing 10% FBS. Cells in the insert were then harvested and analyzed by FACS. To assess the ability of tumor cells to influence migration of myeloid cells, the 24-well Transwell® system with 3 μm pore insert was used (BD Falcon, CA) and cells were seeded as above. At 48 h non-attached cells were collected from the well and from the insert separately, counted and analyzed by FACS for co-expression of the myeloid markers Ly6C, Gr1 and CD11b together with CD79a. To test the effect of anti CD79a antibody stimulation on myeloid cell migration, BM or spleen cells were placed in the insert (3×10^5 cells/insert) with or without addition of anti CD79a (10 μg/ml) to the well. After 48 h cells were collected from the well and from the insert separately, counted and analyzed by flow cytometry for co-expression of the myeloid marker Ly6C, together with CD79a.

Cytokine protein array and ELISA

To assess cytokine secretion from mouse tumor cells, conditioned media from 67NR and 4T1 tumor cell cultures were analyzed for 14 different cytokines (see Supplementary Table S1 for list) using quantitative Aushon Protein Arrays, performed by the manufacturer (Aushon Biosystems, Billerica, MA). To assess cytokine secretion from myeloid cells, semi-quantitative dot-blot based Mouse Cytokine Arrays C1000 (RayBiotech Inc, Norcross GA) were used according to the manufacturer’s instructions. After blocking with BSA, the arrays were incubated with a 1:1 dilution in blocking buffer with supernatant from Ly6C^+ BM myeloid cells of SCID mice (2×10^6/well in 24 well plate) cultured with anti-CD79a (10 μg/ml) or isotype control for 48 h. A parallel set of arrays was used to probe cytokine expression in the supernatant from myeloid cells that had been exposed to 4T1 conditioned medium (at a final concentration of 20%) for 48 h. 4T1 conditioned medium alone (20% final) was used as a control. Signal was developed according to the manufacturer’s protocol, and imaged by exposure of the membrane to film. Relative spot intensity was determined using ImageJ. The concentration of IL-6 and CCL22 in culture supernatants was quantitated by Quantikine ELISA (R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions. Immunofluorescence staining

Lungs from naive or tumor-bearing mice were removed, inflated with 10% formalin, maintained in 10% formalin overnight, paraffin embedded and sections (5-6 μm) were prepared. Tissue sections were heated (60°C, 20 min), deparaffinized (3 washes in xylenes), rehydrated by successive washes in absolute ethanol, 95% ethanol, 75% ethanol and deionized water. Antigen retrieval was performed at 125°C for 20 min in pH 9.0 EDTA buffer. Tissue sections were incubated for 1 hour in a blocking solution (PBS, 5% goat serum, 0.05% Tween 20). Immunofluorescence staining was performed using the following primary antibodies for mouse samples: Gr1(RB6-8C5) and F4/80 (BM8) from BioLegend, CD79a (HM79-11, AbD-Serotec) and CD79a polyclonal IgG (Santa Cruz, CA). For human samples the following antibodies were used: CD11b (CBRM1/5), CD79a (ZL7-4), CD79b (CB3-1) (BioLegend, CA). Primary antibodies were incubated overnight at 4°C. Tissue sections were washed twice and stained with the following secondary antibodies: Alexa 546-conjugated donkey anti-goat, Invitrogen, FITC conjugated goat anti-Armenian hamster, Abcam. DyLight™649 conjugated goat anti-rat IgG, BioLegend. Secondary antibodies were stained for 2 hours, washed 3 times, mounted with ProLong® Gold Antifade Reagent with DAPI (Invitrogen) and covered with a cover slip. Immunofluorescence staining was observed and photographed using a Zeiss 710 epi-fluorescence microscope. For quantification of lung infiltrating Gr1^+CD79a^+ myeloid cells, normal and metastasis bearing lung sections were stained with anti Gr1 (DyLight™649) and anti CD79a-11 (FTTC). Images of 20X magnification were analyzed. Gr1^+CD79a-11^+ and Gr1^+CD79a-11^ myeloid cells were counted in normal lung, in uninvolved lung tissue from metastasis-bearing lung and in the lung
metastases. Analysis was done for 3 samples in each group, assessing five fields (each 300 μm²) in each sample.

Bone marrow cell differentiation
Bone marrow cells from naïve SCID mice were stimulated with anti-CD79a-V20 (5 μg/ml) for 96 h with or without added GM-CSF (20 ng/ml) in low (2%) normal mouse serum. At 96 h cells were harvested and stained for analysis by flow cytometry. Live cells were assessed by flow cytometry as the negative population for 7-AAD staining. The effect of anti CD79a-V20 on myeloid cells differentiation status was assessed using immature (CD11b+Gr1+), granulocytic (Gr1+), and macrophage (F4/80) markers.

Statistical Analysis. Results were analyzed by ANOVA (post hoc test Dunnett’s Multiple Comparison Analysis), or the Kruskal-Wallis test (post hoc test Dunn’s Multiple Comparison Analysis) using Graph Pad Prism 5.0 b.

Supporting Information
Figure S1 Immature BM myeloid cells co-express the myeloid markers CD11b, Gr1 and the Gr1 subunit Ly6C.
A single cell suspension was prepared from naïve BM cells and analyzed by FACS for the different myeloid markers. The red box indicates the immature myeloid cells. All of the CD11b+Gr1+ cells are positive for Ly6C.

(TIF)

Figure S2 CD79a is expressed on naïve immature myeloid cells. (A) Cells isolated from the different organs of naïve Balb/c mice were analyzed by flow cytometry for co-expression of the myeloid marker Ly6C with CD79a/b as detected by the CD79-11 antibody. (B) Flow cytometry of immune cells in (A) showing that the CD79a subunit expressed on myeloid cells is CD79a (only detected by CD79-11 antibody) and not CD79b (detected by both CD79-12), whereas mature B cells express both markers. The box indicates the immature myeloid population. (C) Analysis of expression of additional B cell markers on leukocytes from bone marrow. Markers of mature B-cells are not expressed on the majority of the CD11b⁺ myeloid cells. The small population of CD11b⁺ cells that express B220 and CD19 probably represents plasmacytoid dendritic cells.

(TIF)

Table S1 Cytokines secreted by the metastatic 4T1 and the non-metastatic 67NR cell lines. Cell-conditioned media from 3 independent cultures of each of the 4T1 and 67NR cell lines (at 80% confluence) were collected and analyzed for cytokine level by quantitative multiplex cytokine array (Aushon Search-Light, MA). Cytokine levels are expressed in pg/ml and results are mean ± SEM.

(A)

Acknowledgments
We thank Mr. Anthony W. Vieira, Ms. Ellen S. Gamble and Ms. Meghan Siritzky for excellent technical assistance with experiments.

Author Contributions
Conceived and designed the experiments: DL, LMW. Performed the experiments: DL, YY, AR, DW. Analyzed the data: DL, AR, LMW. Contributed reagents/materials/analysis tools: SB, ML, JT. Wrote the paper: DL, LMW. Contributed suggestions for experiments/suggestions for data analysis/manuscript editing: LY.

References
1. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162–174.
2. Sica A, Bronte V (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155–1166.
3. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK (2012) Cross-talk between myeloid-derived suppressor cells (MDSCs), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22: 275–281.
4. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, et al. (2004) Expansion of myeloid immune suppressor Gr1⁺Gr1−CD11b⁺ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409–421.
5. Yan HH, Pickup M, Pang Y, Gorskà AE, Li Z, et al. (2010) Gr-1CD11b+CD123+ Myeloid Cells Tip the Balance of Immune Protection to Tumor Promotion in the Premetastatic Lung. Cancer Res 70: 6139–6149.
6. Zsmuteg A, Christofori G (2012) Myeloid cells and lymphangiogenesis. Cold Spring Harb Perspect Med 2: a006694.
7. Erler J, Benezeth KL, Cox TR, Lang G, Bird D, et al. (2009) Hypoxia-induced hyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15: 35–44.
8. Ahnand B, Clark JJ, Nikitina E, van BJ, English NR, et al. (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166: 678–689.
9. Kaplan RN, Riha RD, Zacharoulis S, Bramley AH, Vincent L, et al. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 438: 820–827.
10. Huang B, Pan PY, Li Q, Sato AI, Levy DE, et al. (2006) Gr1−CD11b− immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66: 1123–1131.
11. Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, et al. (2012) Tumor-infiltrating mononuclear myeloid-derived suppressor cells mediate CC chemokine receptor 5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol 189: 5602–5611.
12. Youn NJ, Nagaraj S, Collazo M, Gabrilovich DI (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181: 5791–5802.
13. Dumitru CA, Moses K, Trelfalski S, Lang S, Brondusa S (2012) Neutrophil and granulocytic myeloid-derived suppressor cells: immunomodulatory, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 61: 1155–1167.
27. Kozlov I, Beason K, Yu C, Hughson M (2005) CD79a expression in acute myeloid leukemia (AML) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity. Cancer Genet Cytogenet 163: 62–67.

28. Adakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399-1405.

29. Yang L, Huang J, Ren X, Gorska AE, Chytil A, et al. (2008) Abrogation of TGF-beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13: 23–33.

30. Koyama M, Ishihara K, Karasuyama H, Cordell JL, Iwamoto A, Nakamura T (1997) CD79 alpha/CD79 beta heterodimers are expressed on pre-B cell surfaces without associated mu heavy chain. Int Immunol 9: 1767-1772.

31. Xie H, Ye M, Feng R, Graf T (2004) Stepwise reprogramming of B cells into macrophages. Cell 117: 663-676.

32. Yu D, Allman D, Goldschmidt MH, Atkinson ML, Monroe JG, et al. (2003) Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood 101: 1930–1955.

33. Chiang MY, Monroe JG (2001) Role for transcription Pax5A factor in maintaining commitment to the B cell lineage by selective inhibition of granulocyte-macrophage colony-stimulating factor receptor expression. J Immunol 166: 6091-6098.

34. Sumida K, Wakiya D, Narita Y, Masuko K, Terada S, et al. (2012) Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur J Immunol 42: 2060-2072.

35. Faget J, Biota C, Bachelot T, Gobert M, Treilleux I, et al. (2011) Early detection of tumor cells by innate immune cells leads to Treg recruitment through CCL22 production by tumor cells. J Exp Med 199: 855–865.

36. Reichlin A, Gazumyan A, Nagaoka H, Kirsch KH, Kraus M, et al. (2004) A B cell receptor with two Igalpha cytoplasmic domains supports development of mature but anergic B cells. J Exp Med 199: 855–865.

37. Bhargava P, Kallakury BV, Ross JS, Azumi N, Bagg A (2007) CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone-dependent manner. Am J Clin Pathol 128: 257–264.

38. Benlagha K, Guglielmi P, Cooper MD, Lassoued K (1999) Modifications of Igalpha and Igbeta expression as a function of B lineage differentiation. J Biol Chem 274: 19309–19316.

39. Katsura Y (2002) Definition of lymphoid progenitors. Nat Rev Immunol 2: 127–132.

40. Kawamoto H, Wada H, Katsura Y (2010). A revised scheme for developmental pathways of hematopoietic cells: the myeloid-basal model. Int Immunol 22: 65–70.

41. Pelanda R, Braun U, Hobeika E, Nusenzweig MC, Roth M (2002) B cell progenitors are arrested in maturation but have intact VDJ recombination in the absence of Igalpha and Igbeta. J Immunol 169: 865-872.

42. Fuentes-Panana EM, Bannish G, Karnell FG, Trelil JR, Monroe JG (2006) Analysis of the individual contributions of Igbeta (CD79b)- and Igbeta (CD79b)-mediated signaling for bone marrow B cell development and peripheral B cell maturation. J Immunol 177: 7913-7922.

43. Pike KA, Iacampo S, Friedmann JE, Raincliffe MJ (2004) The cytoplasmic domain of Ig alpha is necessary and sufficient to support efficient early B cell development. J Immunol 172: 2210-2218.

44. Matsuo T, Nomura J, Kuwashara K, Igarashi H, Inui S, et al. (1993) Cross-linking of B cell receptor-related MR-1 molecule induces protein tyrosine phosphorylation in early B lineage cells. J Immunol 150: 3766–3775.

45. Schafer ZT, Brugger JS (2007) IL-6 involvement in epithelial cancers. J Clin Invest 117: 3660–3663.

46. Hong DS, Angelo LS, Kurzrock R (2007) Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 110: 1911–1928.

47. Wu CT, Hsieh CC, Lin CC, Chen WC, Hong JH, et al. (2012) Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med (Berl) 90: 1345–1355.

48. Korkaya H, Kim GL, Davis A, Malik F, Henry NL, et al. (2012) Activation of an IL-6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 47: 570–584.

49. Iliopoulos D, Hirsch HA, Wang G, Struhl K (2011) Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A 108: 1397–1402.

50. Abram CL, Lowell CA (2007) The expanding role for ITAM-based signaling pathways in immune cells. Sci STKE 2007: re2.

51. Hamerman JA, Ni M, Kilbourn JR, Chu CL, Lowell CA (2009) The expanding roles of ITAM adapters FcRgamma and DAP12 in myeloid cells. Immuno Rev 232: 42–58.

52. Hamerman JA, Lanier LL (2006) Inhibition of immune responses by ITAM-bearing receptors. Sci STKE 2006: re1.

53. Ishakibah LB (2009) Cross-regulation of signaling by ITAM-associated receptors. Nat Immunol 10: 549–547.

54. Sancho D, Reina e Sousa (2012) Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol 30: 491–529.

55. Patterson HC, Kraus M, Kim YM, Ploegh H, Rajewsky K (2006) The B cell receptor promotes B cell activation and proliferation through a non-ITAM tyrosine in the Igalpha cytoplasmic domain. Immunity 25: 55–63.

56. Friedberg JW, Sharmar J, Sweetenham J, Johnston PB, Vose JM, et al. (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115: 2578–2585.

57. Woyach JA, Johnson AJ, Byrd JC (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 119: 1175–1184.

58. Park SR, Speranza G, Pickar R, Wright JJ, Kinders RJ, et al. (2013) A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas. Cancer Chemother Pharmacol 71: 981–990.

59. Day GP, Carter J, Bruton C, Espin G, Cane B, et al. (2009) Lenitivimus-mediated bifunctional cell labeling for in vivo melanoma study. Pigment Cell Melanoma Res 22: 283–295.

60. Guy CT, Cardiff RD, Muller WJ (1999) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954–961.

61. Xu X, Wagner KU, Larson D, Weaver Z, Li C, et al. (1999) Conditional mutation of Bcr/Abl in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22: 37–43.

62. Figueroa JD, Flanders KC, Garcia-Closas M, Anderson WF, Yang XR, et al. (2009) Expression of TGF-beta signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics. Breast Cancer Res Treat. 117: 3660–3663.

63. Parish CR, Giddlen MH, Qash BJ, Warren HS (2009) Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation. Curr Protoc Immunol Chapter 4: Unit4.